header logo image


Page 271«..1020..270271272273..280290..»

Longevity and Anti-senescence Therapy Market Growth and Current Status of Industry Surveyed in New Research Report | (2020-2027) – The…

December 4th, 2020 12:28 am

Market Expertz latest study, titled Global Longevity and Anti-senescence Therapy Market, sheds light on the crucial aspects of the global Longevity and Anti-senescence Therapy market. The report aims to help readers accurately estimate the global market growth rate over the forecast period (2020-2027). Our market research team has meticulously performed quantitative and qualitative assessments of the Longevity and Anti-senescence Therapy market dynamics, considering a slew of factors, including market penetration, product portfolios, end-user industries, pricing structure, and the key drivers, constraints, opportunities, and challenges predominantly affecting market growth.

The latest market study broadly segments the industry based on the product type range, application gamut, end-use industry, key regions, and the competitive background. One of the central components of the report is a detailed explanation of the gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and the financial standing of the leading market players. The developmental scope of the Longevity and Anti-senescence Therapy markets new entrants and established companies has also been emphasized in the report.

Request a sample copy of the report to understand the structure of the complete [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/97708

Competitive Terrain:

The global Longevity and Anti-senescence Therapy market is highly consolidated due to the presence of numerous companies operating across this industry. The report depicts the current market standing of these companies, their past performances, demand and supply graphs, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market. The leading market contenders listed in the report are:

Market segments by Top Manufacturers:

CohBarTA SciencesUnity BiotechnologyAgeX Therapeutics?IncPowerVision Inc.

The latest report is inclusive of an extensive coverage of the significant impact of the COVID-19 pandemic on the Longevity and Anti-senescence Therapy business sector. The coronavirus outbreak has drastically impacted the global economic landscape, and consequently, this particular business vertical. Therefore, the report provides the reader with a clear concept of the current scenario of this business vertical, estimating its COVID-19 aftereffects.

Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/97708

Product Type SegmentationHemolytic Drug TherapyGene TherapyImmunotherapyOther Stem Cell Therapies

Industry SegmentationHospitalMedical Service InstitutionDrug and Device Sales

Geographical Scenario:

In this section of the report, market analysts have provided valuable insights into the geographical segmentation of the Longevity and Anti-senescence Therapy market. They have further estimated the current and future market valuations on the basis of the demand-supply dynamics and pricing structure of the leading regional segments. Moreover, the growth prospects of each regional segment have been meticulously extensively discussed in the report.

The global Longevity and Anti-senescence Therapy market is classified into the following regions:

Browse the full report description, along with the ToCs and List of Facts and Figures @ https://www.marketexpertz.com/industry-overview/global-2020-longevity-and-anti-senescence-therapy-market

Highlights of the Table of Contents:

1.1 Research Scope

1.2 Key Longevity and Anti-senescence Therapy market segments

1.3 Target players

1.4 Market analysis by type

1.5 Market analysis by application

1.6 Key learning objectives

1.7 Report timeline

2.1 Global Longevity and Anti-senescence Therapy market size

2.2 Latest trends of the Longevity and Anti-senescence Therapy market by region

2.3 Key corporate trends

3.1 Global Longevity and Anti-senescence Therapy size by manufacturers

3.2 Global Longevity and Anti-senescence Therapy market key players

3.3 Products/solutions/services of major players

3.4 New entrants in the Longevity and Anti-senescence Therapy market

3.5 Mergers, acquisitions, joint ventures, and expansion plans

4.1 Global Longevity and Anti-senescence Therapy Sales by Product

4.2 Global Longevity and Anti-senescence Therapy by Product Revenue

Buy your copy [emailprotected] https://www.marketexpertz.com/checkout-form/97708

Thank you for reading our report. To find out more details on the report or to inquire about its customization, please contact us. We will offer you a report well-suited to your requirements.

See the original post:
Longevity and Anti-senescence Therapy Market Growth and Current Status of Industry Surveyed in New Research Report | (2020-2027) - The...

Read More...

What Is the Okinawa Diet? – Okinawa Diet Plan, Benefits, and More – GoodHousekeeping.com

December 4th, 2020 12:28 am

Journey to a Japanese archipelago in the South Pacific and you'll find a community of island dwellers who consistently live for over 100 years. The astounding longevity of the Okinawans has prompted extensive scientific study into the particular habits that may lead to such long, healthy lives. Instead of finding a proverbial fountain of youth, researchers realized that the unique Okinawa diet and strong social networks have helped these centenarians slow the aging process.

Even if you live on other side of the globe, following a similar eating style may help promote good health. Here's what you should know about the Okinawa diet:

"The traditional Okinawan diet is very produce-rich, making it abundant in phytonutrients and antioxidants, which is the likely reason for its associated health benefits and anti-aging properties," says Stefani Sassos, MS, RDN., Registered Dietitian for the Good Housekeeping Institute. "The Okinawan diet limits meat, refined grains, saturated fat, sugar, salt and full-fat dairy products, which tend to have more inflammatory properties."

The National Institute of Aging and National Geographic have identified the Okinawa diet as a Blue Zone diet, meaning it's specifically associated with longevity. "Though they arent exclusively vegan, a focus on plant-based eating is a common theme among the Blue Zone diets," Sassos says.

The vast majority of the Okinawa diet primarily consists of green and yellow vegetables, root vegetables, soy-based foods, and mushrooms. Okinawans eat fish, meat, dairy, and grains like rice in much smaller amounts. Some examples of foods common to Okinawa diet include:

The diet typically does not include beef, processed meat, eggs, cheese, milk, and processed carbohydrates like sugary sweets and snacks.

"While the Okinawan diet is low in refined carbohydrates, that doesnt mean the diet itself is low-carb," Sassos says. "In fact, Okinawans are known for their high intake of unrefined carbohydrates like root vegetables and green-yellow vegetables, a staple of their diet being sweet potatoes."

Because some Okinawan foods like salted fish and miso can contain high levels of sodium, talk to your doctor before adopting this eating plan especially if you've been instructed to follow a low-sodium diet.

Okinawans eat regular meals, but the philosophy they follow at each meal makes a key difference. "The Okinawan phrase hara hachi bu is said before meals to remind Okinawans to stop eating when they are 80% full," Sassos says. "This plays a role in weight management and fighting off obesity."

One reason that Okinawans maintain good health is due to their diet. Like the Mediterranean diet and the DASH diet, this particular eating style is associated with reduced risk of cardiovascular disease and other chronic diseases. Researchers theorize that the low levels of saturated fat, high antioxidant intake, and low glycemic load affect multiple biological mechanisms, like reducing oxidative stress.

Okinawans also form unique social networks at age 5 called moai. One studied moai had met every day for 97 years. If one member did not show up, the other four would walk across the village to check on their friend. In addition to forming these strong friendships, Okinawans prize their families and faith communities. They also move naturally throughout the day, getting active by simply cooking, doing housework, and walking.

"You could certainly lose weight on this type of eating plan, especially with eliminating a slew of higher caloric items like sweets and processed foods and following the hara hachi bu concept," Sassos says. However, the Okinawa diet is not particularly designed for weight loss, unlike other eating plans out there.

"This type of diet can be difficult to follow if you arent living in Okinawa and dont have ready access to special foods from the region," Sassos says. "That being said, we can learn a lot from certain principles of the diet. Emphasizing more whole foods, produce, and plant-forward plates can have a slew of health benefits. Limiting refined processed foods and highly sugary items, as well as eating in moderation, are all important strategies to incorporate into your lifestyle."

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read the original post:
What Is the Okinawa Diet? - Okinawa Diet Plan, Benefits, and More - GoodHousekeeping.com

Read More...

Study Finds That Blackcurrants Are Healthier Than You Think – Longevity LIVE

December 4th, 2020 12:28 am

Blackcurrants have a beneficial effect on the blood glucose response after a meal. They balance the glucose response of ingested sugar by attenuating its rise and delaying its fall. The effect is likely associated with berry-derived polyphenolic compounds, anthocyanins, which are rich in blackcurrants.

The beneficial health effect of blackcurrants was supported by a recent study conducted at the University of Eastern Finland. In the clinical meal study (Maqua) the beneficial effect on postprandial glucose response was achieved by 75 g (1.5 dL) of blackcurrant. This is a remarkably smaller portion size than in earlier studies. Blackcurrants are often consumed with added sugar because of their natural sourness, which may be a cause of concern for health-conscious consumers. However, it seems that sugar consumed with blackcurrants is not as unhealthy as sugar consumed without berries.

The study was a collaboration between the Institute of Public Health and Clinical Nutrition at the University of Eastern Finland and Savonia University of Applied Sciences by utilizing the regional Food Valley ecosystem.

Berries are an important component of a healthy diet. They are rich in vitamins, minerals, dietary fiber, and polyphenols. So far, however, the EU has not authorized health claims for berries. In recent years, there have been many studies monitoring the effects of berries on glucose metabolism. Dark berries, such as blackcurrant and bilberry, had the most convincing results. Black-coloured berries, rich in anthocyanins, seem to attenuate the blood glucose response to added sugar, compared to a control product having the same amount of sugar. The same effect is demonstrated by anthocyanins extracted from blackcurrants. Polyphenolic compounds may slow down the absorption of glucose from the small intestine by interacting with carbohydrate-digesting enzymes and glucose transport proteins. In addition, polyphenolic compounds may reduce oxidative stress and inflammation.

26 healthy participants (22 female, 4 male) consumed three different test products and sugar water as a control product at four separate study visits. The test products were:

Each of them and the control product contained 31 g of available carbohydrates. They also had a similar composition of sugar components. Blood samples were taken before the meals in fasting state. Samples were also taken post-prandially in 15, 30, 45, 60, 90, 120, and 180 minutes after consuming the meal. The samples were analyzed for glucose, insulin, and free fatty acids.

Compared to sugary water, both blackcurrant products had attenuated postprandial glycaemic response. This was seen in reduced maximum glucose and insulin, delayed fall of glucose, and delayed rise of free fatty acids because of hypoglycaemia. The effect was enhanced for the blackcurrant product because of the innovative product base. The results support earlier findings on the beneficial effects of blackcurrants on blood glucose response after a meal, showing the effect with smaller portion size. Over a longer period of time, smaller variations in blood glucose and insulin levels, and improved insulin sensitivity, may decrease the risk of type 2 diabetes.

Blackcurrants are an interesting raw material for the food industry because of their high content of anthocyanins and easy availability. Blackcurrants have potential for being developed into new healthy and tasty products.

Read more here:
Study Finds That Blackcurrants Are Healthier Than You Think - Longevity LIVE

Read More...

Longevity and Anti-senescence Therapy Market size and Key Trends in terms of volume and value 2020-2025 – Express Journal

December 4th, 2020 12:28 am

The recent report on the Longevity and Anti-senescence Therapy market predicts the industrys performance for the upcoming years to help stakeholders in making the right decisions that can potentially garner strong returns. Further, the document provides comprehensive analysis of the key industry trends as well as the opportunities that will ensure an upward growth trajectory in the coming years. It also focuses on developing strategies for challenges faced by the industry. Moreover, an exhaustive discussion of the latest updates including the impact of COVID-19 pandemic is furnished in the study.

Key highlights from COVID-19 impact analysis:

An overview of the regional landscape:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/268954

Other important takeaways from the Longevity and Anti-senescence Therapy market report:

Key aspects listed in the report:

Points Covered in The Report:

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors, etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data and forecast data from 2020 to 2025.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by manufacturer, by region, by type, by application, etc., and custom research can be added according to specific requirements. The report contains a SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Longevity and Anti-senescence Therapy Market. Different strategies implemented by these vendors have been analyzed and studied to gain a competitive edge, create unique product portfolios and increase their market share. The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players. Besides, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

MAJOR TOC OF THE REPORT:

Chapter 1 Industry Overview

Chapter 2 Production Market Analysis

Chapter 3 Sales Market Analysis

Chapter 4 Consumption Market Analysis

Chapter 5 Production, Sales and Consumption Market Comparison Analysis

Chapter 6 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7 Major Product Analysis

Chapter 8 Major Application Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Chapter 14 Appendix

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/268954

Read more:
Longevity and Anti-senescence Therapy Market size and Key Trends in terms of volume and value 2020-2025 - Express Journal

Read More...

4 questions to ask yourself about living to 100 because there’s a chance you will – MarketWatch

December 4th, 2020 12:28 am

As Americans live longer than ever before and the ones born today could expect to celebrate their 90th birthday and beyond there are questions they need to ask themselves.

The University of California, Irvines Institute for Memory Impairments and Neurological Disorders (UCI Mind) has studied elderly individuals as part of its 90+ Study since 2003, analyzing the ways in which nearly 2,000 participants go about their lives in their 90s and 100s, as well as what may have contributed to that longevity and underlying cognitive disabilities they may or may not know they have.

60 Minutes met with a few participants including a World War II veteran and a ballroom dancer six years apart and recently reported that many continued to thrive. Some participants had an iPhone and were on Facebook, and others were exercising in any capacity they could. While a few of the participants were losing their cognitive abilities, others were mentally agile, able to answer questions and formulate calculations at the tops of their heads.

They also remember vivid memories one participant said he recalls buying his first car, a 1931 Chevy convertible, for $18 in a pool hall because the seller needed the money to shoot pool. When asked how old the 99-year-old feels, I always say 69, he told CBS reporter Lesley Stahl.

While these golden agers might seem uncommon now, the future will see many more. Half of children born this decade can expect to see their 103rd or 104th birthday, Claudia Kawas, co-principal investigator of The 90+ Study, told CBS. And if other Americans expect to follow suit, living well into their 80s, 90s or even 100s, theyll need to think carefully about the time ahead of them.

Here are a few questions they can consider:

See: Want to solve the retirement crisis? Invest $7,500 for every baby born in America

How many things will I be when I grow up?

Parents and teachers used to ask children what they wanted to become when they were older, but the question will likely need to change to what jobs as in, plural will people want to take on as an adult, said Joe Coughlin, director of the MIT AgeLab and author of The Longevity Economy. You are seeing in this pandemic a propellant of what education will be like, he said. Theyll have to continue learning.

Some older Americans may already be seeing that, as they switch jobs or advance their careers as technology pushes society forward. There are now social media analysts, data scientists, even remote learning consultants positions that did not exist only a few decades ago. Nancy Schlossberg, an author and former counseling professor, said shes experienced it herself moving from a job as a professor and author to a consultant for Zoom programs on transitions in life.

Workers will need to stay adaptable, Coughlin said, meaning they will need to brush up on the latest skill sets and be ready to grow as their fields change.

Not only can people expect to change jobs and career fields numerous times in their lifetimes, but even what they do in retirement, Schlossberg said. There are six types of retirees, she found in her research, including ones who choose not to have any big plans in retirement and those who start a hobby theyve always longed to try.

With whom will I live this long life?

Choosing a significant other to share lifes journey with may become an even bigger commitment than it already is, especially if you marry in your 30s and expect to live into your 90s, Coughlin said. Were not talking about 25 years or the rarity of 50, he said. Celebrating a golden anniversary, or longer, could become commonplace. But that also depends on if the marriage will last. Of course, many Americans divorce even in their older age and some may choose to stay single, date or find another spouse with whom they can spend their later years.

Not everyone needs a spouse, but when thinking about a long life ahead, individuals do need to think about who may be around them in that time. They should plan for how they expect to interact with children, grandchildren, other family members, friends and even neighbors. A crucial question to get sorted out is this: Who will take care of you when youre old or sick? This may be a significant other, it may be a relative or a family friend, or it may be a health care professional but knowing that answer and discussing it at length with the other person is important to ensuring your wishes are met, as are theirs.

There are also social clubs, online communities and other ways to strike up new friendships. Socializing is an important part of living a long, happy life.

Can I afford it?

Longevity is a blessing, but it can also become a burden if an individual is not adequately prepared financially for this long life. Because of the pandemic, about half of workers over age 55 will be poor or near-poor at 65 years old, defined as living on less than $20,000 a year, according to the New School.

The COVID-19 crisis may make it harder for some Americans to live comfortably in old age perhaps because of a job loss, brief but significant investment losses or the need to withdraw money from a retirement account but even without the pandemic, workers need to think about how their money will last them for decades, not years, in retirement. A healthy 65-year-old could expect to live at least 30 more years in retirement, which means every dollar they have saved and invested will count. Because of this increased longevity, some Americans may choose, or need, to work longer to make ends meet.

You have to worry about getting unlucky and living to 100, Richard Thaler, the 2017 economics Nobel Prize winner, said during a Brookings Institution event last year. Theyll need to focus on saving and preserving those assets, as opposed to spending them down in retirement.

Also see: How robots and your smart fridge can keep you pit of a nursing home

What should I do with all of that time in old age?

What will fulfill you during this next phase of your life? Thats one major question to ask yourself, said Thomas Malone, author of Superminds: The Surprising Power of People and Computers Thinking Together. You can say wisdom is not just the ability to achieve your goals, but to work toward the right goals, he said.

For some, this may be leaving behind a legacy. It sounds philosophical, but one way to determine a persons next steps is to think of what provides the greatest good for the greatest number of people, Malone said. What gives people fulfillment is working toward something bigger than yourself, he said. Finding the answer might become easier as a person ages, because theyll have experiences they can rely on.

But retirement is also a chance to enjoy yourself and take up a hobby or interest you couldnt do in the earlier parts of your life, Malone said.

Coughlin said your life can be broken up into 8,000-day intervals: from birth to college is 8,000 days; from college to midlife is 8,000 days; from midlife to retirement is 8,000 days; and then retirement itself can be another 8,000 days, he said.

How do we want to live life tomorrow? Coughlin asked. Its not just about planning but preparing. We need to physically put things in place about where we live, get around, give and receive care. This is more than putting enough money in the bank its about living longer and better.

View post:
4 questions to ask yourself about living to 100 because there's a chance you will - MarketWatch

Read More...

First Drive: The Fiat 500 EV proves this supermini’s unrivalled longevity – Aberdeen Evening Express

December 4th, 2020 12:28 am

What is it?(Fiat)

Reinventing an icon is never easy, but thats exactly what Fiat was faced with when it decided to update the 500. Its played it safe by keeping the existing model on sale, but in many ways its also undergone a radical change by making the new model fully electric.

Thats right, the new generation 500 cannot be bought with an internal combustion engine. Instead its been completely reinvented with new underpinnings and a new look. As an urban car, on paper, the 500 is the perfect model for electrification, so lets find out if it stacks up.

Pretty much everything except for the name is new. Its the first Fiat Chrysler Automobiles vehicle to be built from the ground up as an electric vehicle, so its perhaps unsurprising that it has led with its most iconic model.

That makes it wider and longer than the outgoing model, gets level two autonomous driving features, a futuristic twist on the classic 500 styling, and two battery size choices with fast charging up to 85kW. Its also offered as both a hatchback and convertible.

The powertrain is impressively compact to maximise space in the cabin. Under the bonnet where an engine would typically live is a power electronic bay, which incorporates various aspects of the powertrain such as the charger module and power inverter. Beneath it sits the electric drive module, which has the motor and differential. Its output is 115bhp (or 94bhp on the smaller battery version) and 220Nm of torque.

Beneath the cabin sits the battery pack, which is available in 42kWh or 23.7kWh capacities, providing up to 199 and 115 miles of range respectively. The smaller battery can charge at a maximum rate of 50kW, which takes 30 minutes to get to 80 per cent of charge, while the larger one can take up to 85kW, which takes 35 minutes to reach 80 per cent.

In previous generations, the 500s trump card has always been its style, and while it hasnt been bad to drive, its far from class leading. However, the new 500 feels like a massive step up. Electric powertrains suit city cars down to the ground and this Fiat is no different.

The electric motor doesnt quite have the immediate kick of acceleration of some EVs, but its much more spritely than a petrol car when driving around town. Its comfortable, too, without suffering from the overly harsh ride some rivals struggle with.

The 500 could have been the worst car ever made and it would still sell by the boatload because Fiat absolutely nailed the retro-modern styling. This new model has seen the most dramatic change yet, because although its unmistakably a 500, its got an ultra-modern edge that would be well-suited to a concept car.

Despite being larger now, its not obvious from the outside, so its still got the charming dinky proportions we know and love. It has a solid front grille with a prominent 500 logo that should be tacky but has been implemented in a classy way, while the ring light around the oval headlights is a simple, modern yet characterful touch.

Again, the interior feels like its moved up a level. This is partly because the starting price is higher, as is the case with all EVs, so they tend to get more premium materials and style to help justify it. However, while the Fiat doesnt necessarily feel more premium, gone is the clunky, fussy interior of old and in its place is a sleek minimalist dashboard.

It has a simplified oval instrument binnacle design, which is about the only similarity with its predecessor. Now, the centre console is simply a prominent screen on the dashboard where most features are controlled from, as well as a few physical buttons below for the air conditioning and gear selection.

Prices start at 19,995 for the hatchback after the government grant, and 26,145 for the convertible. There are four trim levels on the hatchback, while the drop top goes without the entry level Action trim, which is only available with the smaller battery.

Standard equipment includes rear parking sensors, 15-inch alloy wheels, halogen headlights, air conditioning and digital instruments. However, theres no infotainment screen you get a smartphone cradle instead.

Step up to Passion and you get the larger battery, cruise control, automatic air conditioning and a seven-inch infotainment screen with Apple CarPlay and Android Auto. After this, Icon models get a leather steering wheel, passive entry with a wearable key, 16-inch alloy wheels, and 10.25-inch infotainment screen with sat nav.

Finally, the top-spec La Prima trim gets extensive extra equipment, including wireless phone charging, leather seats, 360-degree parking sensors, 17-inch alloy wheels, LED headlights and a six-speaker sound system.

Reinventing the Fiat 500 was a big ask. But you have to say fair play to the Italians because they have managed to find everything thats loved about the previous 500 and packaged it up in a modern-looking car with a future-proof electric powertrain.

Theres now more substance to the 500s style, because its great to drive, more spacious and has ultra-low running costs too. Its safe to say this city cars reign of success is likely to continue for a good while yet.

Read the original:
First Drive: The Fiat 500 EV proves this supermini's unrivalled longevity - Aberdeen Evening Express

Read More...

The White House is hosting indoor holiday parties despite top health officials’ warnings | TheHill – The Hill

December 4th, 2020 12:28 am

The White House is scheduled to hold as many as 20 indoor holiday events this month despite an alarming surge in coronavirus cases and hospitalizations and guidance from public health officials to avoid large indoor gatherings this holiday season.

Leading up to Thanksgiving, the Centers for Disease Control and Prevention (CDC) issued guidance recommending people spend the holiday only with those living in the same household and suggestedcelebrations be held outdoors if possible as the coronavirus raged out of control.

Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.

During an interview just ahead of the holiday, U.S. Surgeon General Jerome Adams pleaded with Americans to avoid large holiday gatherings as the U.S. is at a dire point in the COVID-19 pandemic.

As of Wednesday, a record 98,691 COVID-19 patients were hospitalized across the country while the rolling seven-day average of deathshas surpassed 1,500.

But the White House has moved forward with annual holiday events as the outbreak continues, ignoring warnings from the Trump administrations own public health officials and a pandemic that has left more than 273,000 Americans dead.

The events kicked off Monday after first lady Melania Trump unveiled Christmas decorations.

The Washington Post reports each event will include more than 50 guests, most of whom will not be tested in advance. One such event on Tuesday night included several attendees who were not wearing masks and crowded together, according to NBC News.

White House press secretary Kayleigh McEnany on Wednesday dismissed the health concerns associated with the events.

If you can loot businesses, burn down buildings, engage in protest, you can also go to a Christmas party, McEnany said during a White House briefing.

You can celebrate the holiday of Christmas, and you can do it responsibly, she said.

Stephanie Grisham, Melania Trumps chief of staff, said in a statement on Wednesday that the White House is providing the safest environment possible by having a smaller guest list and mask requirements while encouraging social distancing.

Meanwhile, the head of the CDC warned the U.S. could see another 200,000 coronavirus deaths over the next three months if people dont take mitigation measures such as mask-wearing and social distancing seriously.

The reality is December and January and February are going to be rough times. I actually believe theyre going to be the most difficult in the public health history of this nation, CDC Director Robert Redfield said Wednesday.

WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW

CDC CUTS LENGTH OF COVID-19 QUARANTINE TIME AFTER EXPOSURE

UK BECOMES FIRST WESTERN NATION TO AUTHORIZE COVID-19 VACCINE

CDC DECIDES WHO WILL RECEIVE FIRST DOSES OF COVID-19 VACCINES

CORONAVIRUS EPIDEMIC WAS SPREADING IN US LAST CHRISTMAS, LONG BEFORE IT WAS IDENTIFIED IN CHINA, NEW STUDY FINDS

FAUCI CONFIRMS COVID-19 VACCINE COULD BE READY BY LATE DECEMBER, EARLY 2021

Read the original:
The White House is hosting indoor holiday parties despite top health officials' warnings | TheHill - The Hill

Read More...

BioAge Raises $90M to Treat Aging and Age-related Diseases – GlobeNewswire

December 4th, 2020 12:28 am

Proceeds will support advancement of the companys pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging

Company announces Chief Medical Officer as it prepares to enter clinic in 2021 with lead Phase 2-ready therapeutic compounds

RICHMOND, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial entrepreneur, Elad Gil, and included new investors Kaiser Foundation Hospitals, AARP Foundation (through the RockCreek Impact Fund) and Phi-X Capital, the fund of genomics entrepreneur Mostafa Ronaghi, among others. Current investors including Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures, and others also participated.

These additional funds will support advancement of our systems biology and data-driven platform to map the key pathways that drive human aging and our pipeline of medicines that target these pathways to reverse or eradicate diseases and extend healthspan, said Kristen Fortney, PhD, co-founder and chief executive officer. We look forward to advancing our first platform-derived therapies, BGE-117 and BGE-175 into clinical trials in the first half of 2021.

BioAge is at the forefront of understanding scientific drivers of aging with its unique and cutting-edge systems biology platform. We believe their approach has the potential to unlock the underlying pathologies of many diseases, such as Alzheimers, cardiovascular disease, and frailty, that disproportionately affect older populations, said Vijay Pande, PhD, general partner at Andreessen Horowitz.

Drugs that target aging have potential to treat several morbid diseases and improve the lives of older adults. BioAge has built a proprietary engine to analyze molecular signatures in aging populations, and to advance data-driven hypotheses to identify existing clinical-stage drugs that are ready for Phase 2 efficacy trials in age-related diseases. Im excited to work with them as they scale their platform and develop multiple therapies to improve the health of older individuals, said Elad Gil, PhD, entrepreneur and investor.

Proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increase healthspan and lifespan, augment BioAges artificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Separately, the company announced that Paul Rubin, M.D. will lead its clinical development efforts as chief medical officer. Dr. Rubin, a veteran biopharmaceutical drug developer, brings extensive experience from early discovery, late stage development and ultimate drug approvals across a wide variety of therapeutic areas in global geographies. In former roles heading development at Sepracor, GSK and Abbott, Dr. Rubin has been responsible for the clinical development and approval of more than ten products. Prior to BioAge, he was most recently executive vice president, Research and Development for MiRagen and held a similar role at Xoma, two biotechnology companies. Dr. Rubin earned his M.D. at Rush Medical College, Chicago.

Dr. Rubin commented, I am thrilled to be leading the BioAge clinical development team at this exciting time. Our platform provides a unique opportunity to identify targets relevant to the aging process and diseases associated with this process. Diseases common to older patients are often ignored despite their direct association with morbidity, mortality and decreased quality of life. The first two drugs from our pipeline are ready to begin Phase 2 trials in indications targeting serious conditions in elderly populations that presently have no good therapeutic options. A key aspect of our strategy is to initiate efficient human clinical trials that will demonstrate that our drugs can address age-related deficiencies in acute conditions, which may expedite approval and serve as a gateway to the treatment of chronic diseases, resulting in healthy aging.

About the BioAge Platform

The BioAge platform identifies key drug targets that will impact aging. The companys proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan and disease outcomes. BioAge has built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. BioAges pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

About BioAge

BioAge is a privately-held biotechnology company developing proprietary drugs to treat aging and aging- related diseases. Since its founding in 2015, the Company has raised $127 million in venture capital funding to back its AI-driven approach to map the molecular pathways that impact human longevity. BioAges mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the companys website at http://www.bioagelabs.com.

Source: BioAge Labs, Inc.

Contact Information:

BioAge | peng@bioagelabs.com

Media | swheeler@wheelhouselsa.com

Read more from the original source:
BioAge Raises $90M to Treat Aging and Age-related Diseases - GlobeNewswire

Read More...

How the pandemic enabled a robot revolution – Politico

December 4th, 2020 12:27 am

Future Pulse is a new weekly newsletter exploring the rapidly changing world of health care and technology. We call out fads from real advances, chronicle experimentation and investigate the tension between innovation, regulation and privacy. Join the conversation!

JUST WHAT THE ROBOT ORDERED: At several Texas health networks, a friendly-looking robot with a mechanical arm and blinking lights for eyes can be seen whirring around the hospital floor, ferrying lab samples and protective gear for nursing staff. At Bostons Brigham & Womens this summer, a roaming four-legged robot with mounted infrared cameras loped into the emergency department to take patients vital signs. At Los Angeles Adventist Health White Memorial, seven devices the size of mini-fridges zip around to disinfect patient rooms with UV light.

Whether theyre restocking supply rooms or taking patients heart rates, the roving machines could help contain the coronavirus spread by cutting down on possible exposure between staff and patients, health system leaders say. The systems were already in the early stages of piloting robots before the pandemic, but the crisis has generated more interest than ever, robotics experts tell us. The big question is whether to rush to automate is pushing aside viable existing technologies

What were trying to do is introduce ways of really preserving safety of health care personnel by having assistance ... in doing tasks that can essentially be handed off to a robot, says MIT assistant professor Giovanni Traverso, part of the research team that sent Boston Dynamics dog-like robot named Spot into Brigham & Womens exam rooms to measure vital signs like temperature and blood pressure.

Rich Pedroncelli/AP Photo

Stopped at the door: Still, there are lots of mundane challenges some robots havent been able to overcome, like walking up stairs or opening certain types of doors. For robots in general, the standard doorknob is still going to be most challenging, says Andrew Rossi of Diligent Robotics, which created the Moxi robot used in the Texas health systems.

And anytime the robots are deployed to a new health system, they have to be programmed with new instructions. We have to understand what elevators they use and how they badge in and out of doors and then we have to make adjustments, Rossi said.

Theres much to learn before health systems go all in with robots, MITs Traverso said. His team is exploring whether Boston Dynamics Spot, which retails for about $75,000, is worth the investment. Theyre also considering patients comfort levels with the robot caregivers, which Traverso admits might be a little jarring. In general, though,people are curious and kind of fascinated by this robot, he says.

A simpler approach?: And the biggest question remains is the high-tech way ultimately the better way?

I think we need to further expand our understanding and exposure to robots and see them in different settings, Traverso says. The main question is, do we need that level of sophistication, or are there simpler systems?

Welcome back to Future Pulse, where we explore the convergence of health care and technology. Share your news and feedback: @dariustahir, @ravindranize, @ali_lev, @katymurphy.

Next week, POLITICO will feature a special edition Future Pulse newsletter at the Milken Institute Future of Health Summit. The newsletter takes readers inside one of the most influential gatherings of global health industry leaders and innovators determined to confront and conquer the most significant health challenges. Covid-19 has exposed weaknesses across our health systems, particularly in the treatment of our most vulnerable communities, driving the focus of the 2020 conference on the converging crises of public health, economic insecurity, and social justice.

Michael Anne Kyle @michaelannica "Being in year 5 of a PhD in health policy, I have spent a very large amount of time thinking about waste, moral hazard, unnecessary utilization, consumer decision-making, etc. And yet this week I went to the ED for a broken toe."

The percentage of telehealth visits for mental health services rose in most regions this year, possibly due to increased stress, FAIR Health's president Robin Gelburd says. Variation could be due to differences in substance use disorder diagnoses.

A periodic feature delivering insights from health and tech leaders on how the pandemic is changing the medical system.

Its been less than a year since Chinese scientists shared the Covid-19 genetic sequence, allowing the sprint for a vaccine to commence. Now, states have until the end of this week to tell the federal government how they plan to distribute shots that could be shipped within 24 hours of FDA authorization.

Experts told us they have a multitude of concerns over how the vaccines are allocated to states, wholl get the shots first, and misinformation spreading online.

This is the first time in the history of our country where we are launching multiple novel vaccines all at once that have different dosing, complex scheduling and challenging transport, storage and administration requirements, says Vivian Riefberg, former co-lead of McKinseys U.S. health care practice and now professor of practice at University of Virginias Darden School of Business. Combine this with at least 50 different high level distribution plans (each state) using a range of inexperienced and experienced health care professionals in delivering these products. Then add to that overall market confusion for consumers about the various products. Will we have the right coordinated logistics and campaign to ensure the vast majority of people have timely access and take the vaccine?

David Blumenthal, president of the Commonwealth Fund, which has studied states immunization track records, said his big concern is that many states may not have the resources they need to implement an emergency population-wide immunization plan. Commonwealths research, he said, found huge variation across states in their past success in vaccinating their populations against influenza and other infectious diseases. States also display considerable differences in their ability to immunize populations of color, who suffer disproportionately from Covid-19.

We should leverage primary care providers, who have built trusting relationships with their patients, to educate the public and administer vaccines, says Farzad Mostashari, CEO of Aledade and a former national coordinator for health IT in the Obama administration. As front line workers, they should also be prioritized to receive the vaccines themselves. My biggest concern is that distribution may leave out smaller independent practices, especially in rural and underserved areas where their participation is needed most.

Im less concerned about the nuts and bolts of physical distribution, says Robert Wachter, professor and chair of the Department of Medicine at University of California, San Francisco. Im more concerned about misinformation about side effects ... When you vaccinate 200 million people, a fair number of them will have strokes, cancer or heart attacks in the months after vaccination. Some will spin these into vaccine side effects.

Paul Barrett, deputy director of the NYU Stern Center for Business and Human Rights, worries that the drumbeat of false information online will discourage vaccination. Even before Covid-19, a loud chorus of anti-vaxxer activists, some of whom wrapped their views in various conspiracy theories, had become prominent on the major social media platforms, he said. The coming Covid-vaccination push will almost certainly provoke this contingent into redoubling their activities.

GOOGLES LATEST BID FOR HOSPITAL AND PATIENT DATA: The tech giants forays into health care havent always been welcomed: Its data-collection partnership with the hospital chain Ascension is still under HHS investigation for potential violations of the health privacy law HIPAA. But POLITICO's Mohana Ravindranath writes Googles cloud business is now marketing itself as a technical facilitator for hospitals and insurers, as part of the broader push to share patient data between electronic health records and apps.

Google executives say the effort can relieve hospitals and insurers from the burden of doing a huge technical undertaking on their own. Beyond that, the company is prodding the industry to think bigger about how the digital overhaul can improve patient care, said Google Clouds global health care director Aashima Gupta. This could include new ways to analyze clinical data or building apps that could help patients manage their condition.

Patients may want better access to their health data, but its not clear if theyll trust this latest venture to safeguard theirs. Asked whether shes seen pushback from providers wary of Silicon Valleys expansion into health care, Gupta stressed the company aimed to be sensitive to the needs of clinicians and patients alike. "Consumers are demanding better ways to access their data," she said.

THE PROMISE AND PITFALLS OF AI: Artificial intelligence has been eyed as an easy fix for a health care system facing strain from the pandemic, an aging population and rising costs. Still, the technology raises ethical, legal, economic, and social questions policymakers must confront in order to realize its full potential, concludes a new report to Congress.

Jacquelyn Martin/AP Photo

The Government Accountability Office and the National Academy of Medicine in a joint inquiry acknowledge that AI has shown promise in predicting health outcomes, recommending treatment and helping to record clinical notes, among other tasks. But significant challenges persist. For instance, the technical experts building these tools cant always rely on high-quality data, potentially perpetuating bias that affects patient care. And how these systems work arent always transparent to patients or clinicians, which can undermine trust.

Given those trade-offs, the report offers six paths for Congress and federal regulators to consider, though it offers no recommendations. These include allowing the technology to flourish without government intervention (though GAO noted this could also increase disparities) and working with outside groups to encourage better data sharing and AI testing. Authors noted that groups with proprietary data and technology might be reluctant to participate.

TRUMP ADMIN CEMENTS VIRTUAL CARE CHANGES: The federal Medicare agency on Tuesday approved expanded coverage of telehealth services, ensuring some pandemic policies will last beyond the public health emergency period. Medicare will pay for 60 more telehealth services, though the changes wont do much for patients outside rural areas when the emergency declaration is lifted. Medicare payment law generally restricts telehealth coverage to patients in rural areas, unless Congress makes a change.

Alcoholics Anonymous goes to Zoom, reports the New York Times.

Science Magazine probes HHSs controversial coronavirus data system, alleges discrepancies.

STAT delves into a new artificial intelligence feat from the folks at Google DeepMind: folding proteins.

See the article here:
How the pandemic enabled a robot revolution - Politico

Read More...

Mini kidneys bioprinted in the lab – Lab + Life Scientist

December 4th, 2020 12:25 am

Researchers from the Murdoch Childrens Research Institute (MCRI) and biotech company Organovo have used cutting-edge technology to bioprint miniature human kidneys in the lab, paving the way for new treatments for kidney failure and possibly lab-grown transplants. Their study has been published in the journal Nature Materials.

Like squeezing toothpaste out of a tube, extrusion-based 3D bioprinting uses a bioink made from a stem cell paste, squeezed out through a computer-guided pipette to create artificial living tissue in a dish. According to MCRI Professor Melissa Little, a world leader in modelling the human kidney, this new bioprinting method is faster and more reliable than previous methods, allowing the whole process to be scaled up. 3D bioprinting could now create about 200 mini kidneys in 10 minutes without compromising quality.

From larger than a grain of rice to the size of a fingernail, bioprinted mini kidneys fully resemble a regular-sized kidney, including the tiny tubes and blood vessels that form the organs filtering structures called nephrons. Prof Little said the mini organs will be used to screen drugs to find new treatments for kidney disease or to test if a new drug was likely to injure the kidney.

Drug-induced injury to the kidney is a major side effect and difficult to predict using animal studies; bioprinting human kidneys are a practical approach to testing for toxicity before use, she said.

In the study, researchers tested the toxicity of aminoglycosides a class of antibiotics that commonly damage the kidney. Prof Little said, We found increased death of particular types of cells in the kidneys treated with aminoglycosides.

By generating stem cells from a patient with a genetic kidney disease, and then growing mini kidneys from them, also paves the way for tailoring treatment plans specific to each patient, which could be extended to a range of kidney diseases.

Prof Little said the study also showed that 3D bioprinting of stem cells can produce large enough sheets of kidney tissue needed for transplants. She noted, 3D bioprinting can generate larger amounts of kidney tissue but with precise manipulation of biophysical properties, including cell number and conformation, improving the outcome.

Prof Little said prior to this study the possibility of using mini kidneys to generate transplantable tissue was too far away to contemplate, but that may no longer be the case.

The pathway to renal replacement therapy using stem cell-derived kidney tissue will need a massive increase in the number of nephron structures present in the tissue to be transplanted, she said.

By using extrusion bioprinting, we improved the final nephron count, which will ultimately determine whether we can transplant these tissues into people.

Image credit: stock.adobe.com/au/bluebay2014

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Read more from the original source:
Mini kidneys bioprinted in the lab - Lab + Life Scientist

Read More...

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine – BioSpace

December 4th, 2020 12:25 am

MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has entered into an agreement with Scintec Diagnostics GmbH (Scintec) to acquire TheraPharm GmbH (TheraPharm), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology. TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), lymphoproliferative disorders and immune-mediated diseases (e.g. lupus, and multiple sclerosis). Of particular interest is the demonstrated use of the technology to safely and effectively perform bone marrow conditioning (BMC) prior to bone marrow stem cell transplant.

Telix CEO, Dr. Christian Behrenbruch stated, Telix is committed to extending and improving the lives of patients with serious diseases. As such, the acquisition of TheraPharm and its MTR assets are uniquely aligned to Telixs mission and technical strengths in antibody engineering and radiochemistry. TheraPharms technology has a significant role to play in BMC and stem cell transplantation across a broad range of blood cancers and rare diseases. The current approach to BMC employs highly toxic drugs that have a poor morbidity and mortality profile, and for which many patients are ineligible. MTR offers an excellent safety profile that may greatly expand the number of patients able to undergo life prolonging stem cell transplantation while greatly reducing the hospitalisation burden and cost associated with such procedures.

TheraPharm co-founder and Managing Director, Dr. Klaus Bosslet added, Over the past 5 years, TheraPharm, in collaboration with Dr. Kim Orchard from the University of Southampton (UK), has made excellent progress developing 90Y-besilesomab for the treatment of hematologic cancers and several related conditions including multiple myeloma, leukemia and amyloidosis. This unique asset is a logical addition to Telixs portfolio, offering a potentially rapid development path to a first commercial indication for the treatment of patients with SALA, while at the same time having potentially broad applications for stem cell transplantation in patients with more common cancers of the blood, including multiple myeloma and leukemia. We look forward to joining the Telix team in order to expedite the development of products for this under-served field.

Full transaction details, including financial terms, can be found via the Telix website and ASX portal here.

About Hematopoietic Stem Cell Transplant (HSCT)

Bone marrow conditioning (BMC) followed by hematopoietic stem cell transplantation (HSCT) is presently performed to treat patients with hematologic malignancies (blood cancers), with the objective of extending patient survival or achieving cure. HSCT is also performed for a broad range of non-cancer conditions. HSCT is preferentially performed in countries of high income (Europe >30,000, Americas >20,000, worldwide >65,000 p.a., respectively) and is growing at around 5% annually.

About Systemic Amyloid Light-Chain Amyloidosis (SALA)

SALA is a rare, but serious protein deposition disease, caused by a protein known as amyloid that is produced by abnormal plasma cells residing in the bone marrow. As amyloid accumulates in the organs of the body, organ function will eventually deteriorate, ultimately causing organ failure. SALA has an estimated prevalence of 30,000 and 45,000 in United States and Europe, respectively and while a rare disease, SALA portends a very poor prognosis, with a median survival from diagnosis of ~11 months if untreated.

The current standard of care comprises of induction therapy (typically cyclophosphamide, bortezomib, dexamethasone) plus high dose melphalan BMC, followed by HSCT. This approach is typically only accessible to a small proportion of patients (<20%) who are able to tolerate induction therapy and melphalan BMC.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit http://www.telixpharma.com.

AboutTheraPharm GmbH

TheraPharm is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.

Read more:
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace

Read More...

Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes – Philippine Canadian…

December 4th, 2020 12:25 am

There are more than 300,000 Canadians living with type 1 diabetes (T1D), an autoimmune disease with no known cause or cure, resulting in the dysfunction, damage or loss of pancreatic beta cells that produce insulin in our bodies. People with T1D must treat themselves with insulin several times per day to keep their blood glucose levels normal, and despite their best efforts, they often experience serious, and even life-threatening, complications.

To mark the end of Diabetes Awareness Month, Sonia Sidhu, Member of Parliament for Brampton South, on behalf of the Honourable Patty Hajdu, Minister of Health, announced an investment of $6 million through the CIHR-JDRF Partnership to Defeat Diabetes for two Canadian research teams to accelerate the development of stem cell-based therapies for the treatment of T1D.

Stem cells show great promise as a source of insulin-producing cells that could be transplanted to provide a new source of insulin, to replace dysfunctional, damagedor lost pancreatic beta cells. Canada has a remarkable legacy in leading discoveries in this area. Stem cells were discovered in Toronto in 1961, and in 2000, a team in Edmonton were the first to pioneer transplantation of pancreatic islets (the part of the pancreas that contains insulin-producing cells). These achievements represent important steps toward a treatment that will allow people with T1D to live healthy lives without daily insulin injections.

The research teams are led by Dr. Maria Cristina Nostro at the University Health Network and the University of Toronto and Dr. Francis Lynn at the BC Childrens Hospital Research Institute and the University of British Columbia. The teams will build on Canadas demonstrated research excellence and leadership in clinical islet transplantation, stem cell biology, diabetes, immunology and genetic engineering to accelerate stem cell-based therapies for T1D. They will work in collaboration with other Canadian researchers to tackle some of the biggest scientific challenges that impede our progress in this area and move us closer to a future where people with T1D will no longer rely on insulin therapy.

This funding was provided by the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), and JDRF Canada, through the CIHR-JDRF Partnership to Defeat Diabetes established in 2017. Each partner will invest $3 million over five years. This investment is part of a large research initiative,100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, funded by CIHR and partners. This initiative commemorates the 100th anniversary of the discovery of insulin to be marked in 2021a discovery that changed the lives of millions of Canadians and people around the world and won researchers Sir Frederick Banting and John Macleod the Nobel Prize in Physiology or Medicine.

More here:
Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian...

Read More...

News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon’s graft-versus-host drug -…

December 4th, 2020 12:25 am

Four more biotechs set the terms for their IPOs, lining up yet another busy week on Wall Street.

Silverback Therapeutics, which initially filed for a $100 million raise, is now shooting for $125 million from 7 million shares at a range of $17 to $19. About $70 million is tagged for the companys lead Phase I/Ib antibody-drug conjugate, SBT6050, for advanced or metastatic HER2-expressing solid tumors. Interim data from the Phase I dose-escalation cohorts are expected in the second half of 2021. Another $55 million is set aside for Silverbacks two other candidates, which have yet to reach the clinic.

Kinnate Biopharma is looking for a $170 million raise, and set a $16 to $18 range for its 10 million share offering. About $105 is earmarked for its RAF inhibitors, including its lead preclinical candidate KIN002787 for patients with lung cancer, melanoma and other solid tumors. An IND is coming in the first half of 2021, the company says. Back in August, it hooked a $98 million Series C.

Seer also set its shares at a $16 to $18 range. The company, which is working on next-gen proteome analysis tests, is offering 8.8 million shares, going for a $150 raise. About $65.0 million would go to its Proteograph Product Suite, which already has one collaborator and could have a second by the end of the year.

Sigilon Therapeutics is seeking $101 million from 5.6 million shares at a $17 to $19 range. Between $30 to $35 million will be set aside for its lead candidate, SIG-001, which is in a Phase I/II trial to prevent bleeding episodes in patients with hemophilia A. Another $30 to $35 million would fund a scale-up of the companys GMP manufacturing processes SIG-001 and SIG-005, its preclinical candidate for patients with mucopolysaccharidosis type 1, or MPS-1.

More than 72 biotech and biopharma companies and counting have hit Nasdaq so far this year, and head of healthcare listings Jordan Saxe predicted rounding out the year with just under $14 billion in proceeds.

Kadmons chronic graft-versus-host drug belumosudil is in the FDAs hands.

The agency accepted the biotechs NDA under its real-time oncology review (RTOR) pilot program, and set the PDUFA date for May 30, 2021. The submission was based on positive results from a pivotal, open-label trial dubbed ROCKstar, which enrolled 132 patients who had received at least two prior lines of therapy.

Belumosudil is designed to tamp down the inflammatory response seen after hematopoietic stem cell transplant by blocking Rho-associated coiled-coil kinase 2 (ROCK2). Instead of a comparator arm, Kadmon set the bar at a 30% overall response rate, based on conversations with the FDA. Patients were given 200 mg of the drug either once or twice daily. At six months after the completion of enrollment, Kadmon saw an ORR of 73% and 75% in the respective arms.

Thats it for data, until the full report is read out at ASH in December. The companys stock $KDMN was up 6.68% on Monday, at $4.39 per share.Kadmon was founded by Sam Waksal, the biotech exec who was sentenced to prison for his insider trading conviction involving Martha Stewart.

Hookipa Pharma said no one from a small group of Phase II participants treated with its prophylactic cytomegalovirus vaccine came down with the disease, according to interim results.

The analysis was based on 41 participants 8 of whom received 3 doses, 19 of whom received 2 doses, and 14 of whom received a placebo. Compared to the placebo, researchers saw a 48% reduction in CMV viremia, and a 42% reduction in the use of antiviral therapy. There were no cases of CMV disease in the treatment arm, compared to 2 in the placebo group.

While these interim data are from a small group of patients, they offer early insight into the potential of a three-dose schedule of HB-101 to help protect kidney transplant recipients against CMV disease, CEO Joern Aldag said in a statement.

The candidate is going head-to-head with Modernas mRNA-1647, which produced positive results from a proof-of-concept study back in January. Researchers said they saw an increasing level of neutralizing antibody titers in those who had received a third vaccination.

This could really be a company builder, CEO Stphane Bancel said at the time, adding that the candidate could turn into a $2 billion to $5 billion annual franchise.

Here is the original post:
News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -...

Read More...

Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra’s Latest Product Offerings to…

December 4th, 2020 12:24 am

Pune, India, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. The market was valued at US$ 23,841.5 Million in 2018. Fortune Business Insights states that the market will reach US$ 151,949.5 Million by the end of 2026, thereby exhibiting a CAGR of 26.1%. North America generated maximum revenue of US$ 9,128.2 Million in 2018 and is expected to dominate the global regenerative medicine market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America.

Key Industry Developments:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Increasing Investment in R&D of Regenerative Medicine to Enable Growth

The growing investment in research and development of regenerative medicine has made a significant contribution to the growth of the global market. The increasing investment from private as well as government organizations has had a positive impact on the global market. IN March 2018, SanBio collaborated with Hitachi Chemical Advanced Therapeutics Solutions for developing regenerative medicine across a wide range of applications.

Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines.

Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine Luxturna. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases.

Integra LifeSciences Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer Thin.

Fortune Business Insights some of the leading companies that have made significant growth contributions to the global market. Besides this, the report identifies some of the attractive business strategies that have been adopted by renowned companies in the world.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

List of the leading companies that are operating in the Regenerative Medicine Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Global Regenerative Medicine Market Segmentation:

By Product

Cell Therapy

Gene Therapy

Tissue Engineering

Platelet Rich Plasma

By Application

Orthopedics

Wound Care

Oncology

Others

By Distribution Channel

Hospitals

Clinics

Others

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

SECONDARY DATA SOURCES THAT WE REFER TO:

Have a Look at Related Reports:

Bovine Lactoferrin Market Share Trends & Industry Analysis, By Product (Spray-dried, and Freeze-dried), By Application (Infant Formula, Pharmaceuticals, Dietary Supplements, Food, and Others), and Regional Forecast, 2019-2026

Knee Replacement Market Share & Industry Analysis, By Procedure (Total Knee Arthroplasty, Partial Knee Arthroplasty, and Revision Arthroplasty) By Implant Type (Fixed Bearing, Mobile Bearing, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Electrophysiology Devices Market Share & Industry Analysis, By Type (Ablation Catheters, Diagnostic Catheters, Mapping Systems, Accessories & Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, and Others), By End User (Hospitals & ASCs, and Specialty Clinics & Diagnostic Centers), and Regional Forecast, 2019-2026

Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Prefilled Syringes Market Share & Industry Analysis, By Material (Glass and Plastic) By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System) By Product (Complete Syringe Set and Components & Accessories) By Design (Double-chamber, Multiple-chamber, and Single-chamber) By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Read more from the original source:
Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra's Latest Product Offerings to...

Read More...

Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine – Newswise

December 4th, 2020 12:24 am

Newswise DALLAS Dec. 3, 2020 A team led by UT Southwestern has derived a new intermediate embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing nave embryonic stem cells (those about four days post-fertilization in mice) and primed epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, theres been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named XPSCs from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

These XPSCs have enormous potential. Our study helps open the door to each of these possibilities, says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep nave PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for nave PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF- pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-.

Aiming for the preferred environment for XPSC derivation, Wu and his colleagues placed cells from early mouse embryos into cultures containing chemicals and growth factors that activate all three pathways. These lab-grown cells were extremely stable in culture and able to multiply without developing any further for approximately two years.

Additional experiments showed that these cells met the expectations researchers have long strived to meet of contributing to chimeras and directly differentiating into primordial germ cells. Wu and his colleagues made intraspecies chimeras of mice using cells derived from mice with different coat colors by injecting the cells into early mouse embryos. They also tracked the contributions of the XPSCs by tagging the cells with a fluorescent protein and then identifying them throughout the resulting offsprings body.

Wus team made interspecies chimeras by injecting horse XPSCs into early mouse embryos and allowing the embryos to develop in mice for several days. Surprisingly, although horses have a comparatively long gestational period nearly a year the researchers found that these foreign cells had contributed to mouse organ development, indicating that signals from the mouse cells determine organ developmental timelines.

Like XPSCs from other species, the human cells showed that they were capable of differentiating into a variety of tissues if culture conditions allowed them to progress in development, as well as directly form primordial germ cells in a dish.

Other UTSW researchers who contributed to this study include Leqian Yu, Yulei Wei, Carlos A. Pinzon Arteaga, Masahiro Sakurai, Daniel A. Schmitz, Canbin Zheng, and Emily D. Ballard. Yu and Wu are inventors on a patent application arising from this work.

This study was funded by the Cancer Prevention and Research Institute of Texas (CPRIT No. RR170076), the Hamon Center for Regenerative Science and Medicine, the Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011), and the Asahi Glass Foundation.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 23 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Read the original:
Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine - Newswise

Read More...

Rare-disease foundation backs regenerative research – OutSourcing-Pharma.com

December 4th, 2020 12:24 am

CureDuchenne is a global nonprofit honed in on discovering a cure for Duchenne muscular dystrophy (DMD). Its funding arm, CureDuchenne Ventures, is investing in regenerative medicine firm Mesentech, as part of a joint funding collaboration with the Charles H Hood Foundation (which seeks to advance early-stage research for pediatric conditions).

CureDuchenne Ventures, the funding arm of CureDuchenne (a nonprofit aimed at discovering a cure for Duchenne muscular dystrophy) is investing in Mesentech Inc., a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone. The project is part of a new joint funding collaboration with the Charles H. Hood Foundation (CHF), which seeks to advance early-stage research for pediatric conditions.

Lianna Orlando, CureDuchennes senior director of research, told Outsourcing-Pharma that bone fractures and quality of life are the top two main outcome measures identified by people with DMD.

Individuals with Duchenne are at a high risk for osteoporosis for multiple reasons that include reduced weight-bearing activity (which normally drives development of strong and dense bones), as well as a side-effect of glucocorticoid therapy, and from the effect of the chronic inflammatory response seen in dystrophin-deficient muscles, she said. Fractures in the vertebral bones of the spine are seen in up to 30% of boys with Duchenne, and in addition to being very painful may lead to spine deformity; fractures in the long bones in the arm or the leg are common, and in many cases lead to permanent loss of ambulation.

Whats more, she said, bone fractures can lead to additional complications.

Long bone fractures can release fat emboli into the bloodstream, which can obstruct blood flow in critical places, including the lungsmost often the lungs. Although rare, fat embolism syndrome is a particularly serious complication of bone fractures in Duchenne; in the most severe cases, fat embolisms can lead to death, Orlando told OSP.

The CureDuchenne investment supports Mesentechs lead program, MES-1007, into clinical development and its evaluation in DMD. There are currently no approved therapies for bone wastage for individuals affected by DMD.

Debra Miller, founder and CEO of CureDuchenne, said the investment and collaboration hold the potential to increase the groups impact.

Addressing bone morbidities that contribute to the loss of ambulation could significantly add quality of life to everyone affected by Duchenne, said Miller.

In addition to providing Mesentech with funding, CureDuchenne intends to play an active role in advancing the prodrug technology platform for DMD. Additionally, CureDuchenne chief scientific officer Michael Kelly will join Mesentechs scientific advisory board.

See more here:
Rare-disease foundation backs regenerative research - OutSourcing-Pharma.com

Read More...

Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai – Newswise

December 4th, 2020 12:24 am

Newswise LOS ANGELES (Dec. 1, 2020) -- Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences. Chute assumed his new post Nov. 23.

The selection of Chute, following a national search, reflects the importance of his pioneering research in blood-forming stem cells called hematopoietic stem cells, which can self-renew and generate all cell types found in the blood and immune system. Over the past decade, Chute's lab has discovered several growth factors produced by the cells that line the walls of blood vessels; they play a critical role in blood-forming stem cell regeneration.

"Dr. Chute is an exceptional addition to our faculty," saidDanTheodorescu, MD, PhD, director ofCedars-Sinai Cancer. "His international reputation as a physician-scientist who has made major contributions to stem cell and hematopoietic cell biologywill greatly contribute to positioning the newly created Division of Hematology and Cell Therapy as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for the treatment of blood malignancies."

In addition to his hematopoietic stem cell research, Chute said he looks forward to expanding Cedars-Sinai's CAR T-cell research and therapy. He describes the immune-boosting therapeutic as "transformative" for patients with advanced non-Hodgkinlymphoma,childhood acute lymphoblastic leukemiaand potentially several additional blood cancers.

CAR T-cell therapy is a type of immunotherapy in which patients' own immune cells, called T cells, are collected from their blood, and then an artificial receptor chimeric antigen receptor, or CAR is added to the cells' surface. The receptor enables the modified cells to specifically eradicate cancer cells. The cells are infused back into a patient's body intravenously, where they multiply and attack tumor cells.

"CAR T therapy has become an important treatment option for so many patients with advanced cancer who had no options before," Chute said. "That's what makes CAR T therapy so exciting."

Chute joins Cedars-Sinai from the David Geffen School of Medicine at the UCLA, where he was a professor of Medicine and Radiation Oncology in the Division of Hematology/Oncology and an investigator in the Broad Stem Cell Research Center.

Chute earned his medical degree at Georgetown University. He completed his residency in internal medicine and fellowship in Hematology/Oncology at the National Naval Medical Center. He completed his research training at the National Cancer Institute and the Naval Medical Research Institute.

"I'm excited to join the Cedars-Sinai Cancer faculty because of the opportunity to collaborate with the world-class scientists and top-tier physicians at the cancer center," Chute said. "Cedars-Sinai has always been a leading medical center and is deeply committed to basic and translational research, while also growing the hematology and cellular therapy specialties. I'm eager to play a leading role in that growth."

Clickhereto read more from the Cedars-Sinai Newsroom.

Excerpt from:
Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise

Read More...

How biotech startup Seragen is reworking infertility treatments with regenerative therapies – YourStory

December 4th, 2020 12:24 am

BABIES!

Most people love babies and want a few at some point in their life. But for about 30 million infertile couples in India, alone, babies are an out-of-reach pipe dream.

When Vasanthi Palanivel, a biotech scientist with two decades of experience, saw her friend, Srinivas Chari and his wife undergoing issues with conceiving a baby - and the immense grief that failed treatments caused - she decided to do something about it.

Vasanthis work in the biotech space focused specifically on tissue engineering and stem cell-based treatments, and she decided to use that expertise to develop a regenerative medicine-based infertility treatment, which she claims is better than most traditional treatments available today.

Fertility treatments are expensive - around Rs 1 lakh to Rs 1.25 lakh, per cycle, according to price ranges outlined online by leading IVF treatment centres, have low success rates, and, more importantly, are not covered by insurance. Only a percent of the 30 million infertile couples in India seek IVF treatments, and most of them target very specific problems with synthetic solutions, instead of restoring the patients health, holistically.

She says plasma-based treatments offer breakthroughs where traditional medicine has limited scope. Regenerative treatments are also generally safer, fast-acting, and go beyond just treating the symptoms and problem areas - they help restore organs, tissues and muscles to their ideal state so that the body can function as its supposed to.

So far, the startup has raised angel funding from several individual investors, and is open to more investments. Vasanthi, whos also the startups Chief Scientific Officer, says the venture is profitable, and growing at 100 percent, year on year.

Seragen, founded in 2018, treats over 10 conditions related to male and female infertility, including repeated miscarriages, low testosterone, erectile dysfunction, hormonal imbalance and endometriosis, among others.

The startup gets most of its clients via doctor referrals. On a pre-determined date, the patients case history detailing their medical condition, and their blood sample is collected by Seragens laboratory. The scientists then concoct a personalised fertility medicine, specific to the patients condition, and then send it back to the doctor for administering.

Image credit: Shutterstock

The process takes around 45 minutes, and the medication kicks in roughly 48 hours later.

The cost of the treatment is less than 10 percent of current fertility treatments, she adds.

So far, Seragen has treated over 2,000 patients. Its most requested treatments are for ovarian failures and endometrium. Women over 35 form a large part of the startups patient base.

Currently, the firm is piloting an immunology-based protocol with Indira IVF to target miscarriages - and Vasanthi says she hopes to publish encouraging results soon. The company is also working on a treatment to help prevent the death of mothers after they give birth.

Present in several cities in India already, Seragen is aiming to strengthen its presence domestically, as well as internationally. The startup says it will start operating in South Asian countries like Sri Lanka and Seychelles soon.

The startup competes with generic infertility treatment providers, as well as some stem cell-based therapy providers.

The global regenerative market is expected to reach $17.9 billion by 2025, from $8.5 billion in 2020, and growing at a CAGR of 15.9 percent, a Markets and Markets research report showed. Chronic diseases, genetic disorders and cancers, as well as rising investments in regenerative medicine research is expected to drive most of the growth, the research said.

More:
How biotech startup Seragen is reworking infertility treatments with regenerative therapies - YourStory

Read More...

Resolution Therapeutics Announces a 26.6m Series A Financing from Syncona Ltd – PharmiWeb.com

December 4th, 2020 12:24 am

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

See original here:
Resolution Therapeutics Announces a 26.6m Series A Financing from Syncona Ltd - PharmiWeb.com

Read More...

AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer – Yahoo Finance

December 4th, 2020 12:24 am

VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

Kathys extensive healthcare experience and industry insight are a welcome addition to AVITAs leadership team, said Dr. Mike Perry, AVITA Therapeutics Chief Executive Officer. In particular her broad operational experience within Regenerative Medicine will be critically important as we seek to bring our pipeline products through development and into the markets.

Ms. McGee joins AVITA with over 25 years of biopharmaceutical and life sciences experience, most recently serving as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry. Prior to CnA Consulting, Ms. McGee was the Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President of Operations and General Manager, with responsibility for the companys manufacturing operations in La Jolla, CA. She has also held senior Operations leadership roles at Smith and Nephew and Advanced Tissue Sciences. She earned her Bachelor of Science in chemistry and mathematics from University College Galway Ireland, and holds a Masters degree in Business and Management from Webster University.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

Story continues

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

Continued here:
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer - Yahoo Finance

Read More...

Page 271«..1020..270271272273..280290..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick